<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048944</url>
  </required_header>
  <id_info>
    <org_study_id>NIH/NIDA-2R01DA012289</org_study_id>
    <secondary_id>2R01DA012289</secondary_id>
    <nct_id>NCT01048944</nct_id>
  </id_info>
  <brief_title>Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers</brief_title>
  <official_title>NRT &amp; Bupropion Mechanisms of Effectiveness in Smokers: Phase IV Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Illinois University Carbondale</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern Illinois University Carbondale</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better characterize differences in mood, attention, brain
      activation patterns underlying the beneficial effects of pharmacological treatments
      previously demonstrated to be help individuals successfully quit tobacco smoking. Smokers
      will be randomly assigned to one of three treatments: 1) bupropion sustained release (SR), 2)
      nicotine patch, or 3) placebo patches plus pills across a 45-day period with a 3-week
      intensive post-treatment follow-up. In addition, 20 percent of the subjects will be
      randomized to a delayed-quit control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first aim of this revised proposal is to accurately assess the duration and trajectories
      of smoking abstinence symptoms and associated biobehavioral indices across 66 days of
      quitting smoking in 3 different treatment groups: 1) bupropion SR (BUP), 2) transdermal
      nicotine patch (TNP), and 3) placebo patch plus placebo pill. Study sensitivity and accuracy
      will be maximized by using procedures designed to maximize abstinence and minimize study
      dropout. The second aim is to characterize brain and psychological mechanisms by which BUP
      and TNP promote abstinence. While the efficacies of BUP and TNP in promoting smoking
      abstinence have been repeatedly demonstrated, little is known about the mechanisms mediating
      this efficacy. The final primary goal of this competitive continuation proposal is to
      characterize individual differences in psychological and brain mechanisms mediating the
      beneficial effects of BUP and TNP on smoking abstinence and withdrawal symptoms. A secondary
      goal is to assess the ability of a battery of innovative brain and biobehavioral measures of
      attention and affect to predict relapse.

      To achieve these goals, the effects of quitting smoking with or without the help of TNP and
      BUP will be assessed intensively across 66 days of abstinence. Dependent measures will be
      mood, vigilance, attentional bias to smoking and emotional stimuli, and related physiological
      measures (resting EEG activation and activation asymmetry indices of affective states and
      traits, and event-related potential activity elicited by emotional and smoking stimuli).
      Smokers will be randomly assigned to one of three immediate-quit groups (N = 60 per group):
      (1) bupropion + placebo patch, (2) placebo pill + nicotine patch, and (3) placebo patch +
      placebo pill; or to a fourth (control) group (N = 40) that will quit after the final
      experimental session (after the other subjects have completed their 66-day* abstinence
      period). Subjects in the 3 treatment groups and the control group will have the same set of
      biobehavioral measures assessed during the experimental sessions at the same points in time.
      It is hypothesized that BUP and TNP will have both common and unique mechanisms by which they
      reduce withdrawal symptoms and that gender and personality traits will moderate the effects
      of these treatments. (Note.* To avoid final-session mood and arousal effects subjects will
      actually quit for 67 days, but biobehavioral measures will be collected on the 66th day of
      abstinence.)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Log Brain-wave (EEG) Activity (Power [Microvolts Squared]) From Pre-quit Baseline to 66 Days Post-quit, Assessed at 3, 24, 45, and 66 Days Post-quit.</measure>
    <time_frame>Mean EEG power [microvolts squared] from at baseline, 3, 24, 45, and 66 days post-quit</time_frame>
    <description>Brain-wave activity (EEG) was assessed using electrodes on the subject's scalp, the outputs of which were and quantified by a commercial brain wave machine. EEG was collected at frontal (e.g., Fz) and parietal (e.g., Pz) electrodes while subjects relaxed. EEG was analyzed using computer programs that measured slow-frequency EEG waves known as delta (1.5-4.5 cycles/second [cps]), theta-1 (4.5-6.0 cps), theta-2 (6.0-7.7 cps), and alpha-1 (7.8-10.0 cps), and higher frequency waves. Generally, delta, alpha-1 and theta waves reflect deactivation of the brain activity, while higher frequency waves reflect greater brain activation. Brain activity was quantified as the natural log of EEG power [microvolts squared] as determined by the fast Fourier mathematical algorithm. Days post quit were components of Time. The primary focus was on changes in the individual subject's log theta-1, theta-2, and alpha-1 power at post-quit points in time minus the log values at the pre-quite baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Log of Smoking Withdrawal Scores (Mood, and Depressive Symptoms) From Baseline Across 66 Days of Abstinence</measure>
    <time_frame>Changes in log withdrawal symptoms from baseline through 66 days of abstinence</time_frame>
    <description>Changes in log from baseline in the widely used Shiffman-Jarvik Withdrawal &quot;craving&quot; and &quot;psychological symptom&quot; scores through 66 days of abstinence. Post-quit changes were assessed at days 3, 24, 45, and 66 of abstinence. The maximal range of value raw for craving is from &quot;5&quot; = (no craving) to &quot;47&quot; (maximally strong craving), while that for psychological symptoms is from &quot;5&quot; (no symptoms) to &quot;60&quot; (maximally intense symptoms of across multiple symptoms). Because the subtraction of logs is equivalent to the ratio of the two scores, a difference in logs (base 10) with a value of &quot;1&quot; is equal to an increase by a factor of 10, while a value of &quot;0&quot; is no change, and values of less than &quot;0&quot; are decreases below baseline values.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Bupropion SR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg bid bupropion SR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine Patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>21mg, 14mg, 7mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Patch and Placebo Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Individuals were placed on both a placebo patch that were the same size as active patches given to the Nicotine Patch group and were also given placebo pills were the same size and identically packaged as the active pills (bupropion) given to the Bupropion SR group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed-quit control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Smoke for 67 days while others have quit, then quit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion SR</intervention_name>
    <description>150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.</description>
    <arm_group_label>Bupropion SR</arm_group_label>
    <other_name>ZybanSR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Patch</intervention_name>
    <description>Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days</description>
    <arm_group_label>Nicotine Patch</arm_group_label>
    <other_name>NicodermCQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Patch and Placebo Pill</intervention_name>
    <description>150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days. The placebo patches were given beginning 1st day cessation: 21 mg size (but actually placebo)/24 days, 14 mg size (actually placebo)/ 14 mg size (actually placebo) 14 days/, 7 mg size (actually placebo)/7 days</description>
    <arm_group_label>Placebo Patch and Placebo Pill</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Inclusion Criteria:

          -  Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-IV)
             diagnosis of nicotine dependence with psychological dependence

          -  Smokes at least 10 cigarettes per day for the three months prior to enrollment

          -  Currently seeking treatment for nicotine dependence

          -  Medically healthy on the basis of physical examination and medical history, vital
             signs,

          -  Females must use an effective method of contraception for the duration of the study

        Exclusion Criteria:

          -  DSM-IV diagnosis of abuse or dependence on alcohol or drugs other than nicotine

          -  Current Axis I diagnosis or current treatment with psychotropic medications within the
             three months prior to enrollment

          -  History of schizophrenia or other psychotic disorders, bipolar disorder, or anxiety
             disorders

          -  Currently seeking treatment for nicotine disorders

          -  History of seizures or head trauma with loss of consciousness, brain contusion, or
             fracture

          -  History of significant recent violent behavior

          -  Blood pressure greater than 150/90

          -  History of eating disorders

          -  History of allergic reaction to any of the study medications

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David G Gilbert, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Illinois University Carbondale</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Illinois University</name>
      <address>
        <city>Carbondale</city>
        <state>Illinois</state>
        <zip>62901-6502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <results_first_submitted>May 19, 2014</results_first_submitted>
  <results_first_submitted_qc>November 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2014</results_first_posted>
  <last_update_submitted>November 18, 2014</last_update_submitted>
  <last_update_submitted_qc>November 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southern Illinois University Carbondale</investigator_affiliation>
    <investigator_full_name>David Gilbert</investigator_full_name>
    <investigator_title>Professor of Psychology</investigator_title>
  </responsible_party>
  <keyword>Electroencephalography</keyword>
  <keyword>nicotine</keyword>
  <keyword>bupropion</keyword>
  <keyword>attention</keyword>
  <keyword>drug withdrawal symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment: 9/01/06 to 9/01/11. Recruitment was throughout Carbondale and surrounding communities and occurred with newspaper ads, flyers, radio and television presentations. Recruitment was more challenging than expected because of the large time commitment and high prevalence of psychoactive medication and drug use (exclusionary criteria).</recruitment_details>
      <pre_assignment_details>After consent subjects and the completion of their first experimental session subjects were randomly assigned to one of 4 treatment arms: 197 signed the consent, 126 completed the first experimental session and were subsequently randomly assigned to a treatment condition.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bupropion Sustained Release (SR)</title>
          <description>150 mg bid bupropion SR
Bupropion SR: 150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.</description>
        </group>
        <group group_id="P2">
          <title>Nicotine Patch</title>
          <description>21mg, 14mg, 7mg
Nicotine: Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days</description>
        </group>
        <group group_id="P3">
          <title>Placebo Patch and Placebo Pill</title>
          <description>Placebo patch same size as active patches
Placebo pill and Placebo Patch: 150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days.</description>
        </group>
        <group group_id="P4">
          <title>Delayed-quit Control</title>
          <description>Smoke for 67 days while others have quit, then quit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Personality trait questionnaires, history of psychiatric disorders, SES, age, smoking and drug use history.</population>
      <group_list>
        <group group_id="B1">
          <title>Bupropion SR</title>
          <description>150 mg bid bupropion SR
Bupropion SR: 150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.</description>
        </group>
        <group group_id="B2">
          <title>Nicotine Patch</title>
          <description>21mg, 14mg, 7mg
Nicotine: Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days</description>
        </group>
        <group group_id="B3">
          <title>Placebo Patch and Placebo Pill</title>
          <description>Placebo patch same size as active patches
Placebo pill and Placebo Patch: 150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days.</description>
        </group>
        <group group_id="B4">
          <title>Delayed-quit Control</title>
          <description>Smoke for 67 days while others have quit, then quit.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.85" spread="11.76"/>
                    <measurement group_id="B2" value="30.84" spread="11.00"/>
                    <measurement group_id="B3" value="31.49" spread="10.44"/>
                    <measurement group_id="B4" value="26.8" spread="10.42"/>
                    <measurement group_id="B5" value="30.64" spread="10.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Log Brain-wave (EEG) Activity (Power [Microvolts Squared]) From Pre-quit Baseline to 66 Days Post-quit, Assessed at 3, 24, 45, and 66 Days Post-quit.</title>
        <description>Brain-wave activity (EEG) was assessed using electrodes on the subject's scalp, the outputs of which were and quantified by a commercial brain wave machine. EEG was collected at frontal (e.g., Fz) and parietal (e.g., Pz) electrodes while subjects relaxed. EEG was analyzed using computer programs that measured slow-frequency EEG waves known as delta (1.5-4.5 cycles/second [cps]), theta-1 (4.5-6.0 cps), theta-2 (6.0-7.7 cps), and alpha-1 (7.8-10.0 cps), and higher frequency waves. Generally, delta, alpha-1 and theta waves reflect deactivation of the brain activity, while higher frequency waves reflect greater brain activation. Brain activity was quantified as the natural log of EEG power [microvolts squared] as determined by the fast Fourier mathematical algorithm. Days post quit were components of Time. The primary focus was on changes in the individual subject's log theta-1, theta-2, and alpha-1 power at post-quit points in time minus the log values at the pre-quite baseline.</description>
        <time_frame>Mean EEG power [microvolts squared] from at baseline, 3, 24, 45, and 66 days post-quit</time_frame>
        <population>For the currently reported analyses, only individuals complying with the study requirements, including biochemically verified smoking abstinence, were assessed. Future analyses will include individuals who complied to certain critical endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Patch</title>
            <description>21mg, 14mg, 7mg
Nicotine: Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days</description>
          </group>
          <group group_id="O2">
            <title>Bupropion SR</title>
            <description>150 mg bid bupropion SR
Bupropion SR: 150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Patch and Placebo Pill</title>
            <description>Placebo patch same size as active patches
Placebo pill and Placebo Patch: 150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days.</description>
          </group>
          <group group_id="O4">
            <title>Delayed-quit Control</title>
            <description>Smoke for 67 days while others have quit, then quit.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Log Brain-wave (EEG) Activity (Power [Microvolts Squared]) From Pre-quit Baseline to 66 Days Post-quit, Assessed at 3, 24, 45, and 66 Days Post-quit.</title>
          <description>Brain-wave activity (EEG) was assessed using electrodes on the subject's scalp, the outputs of which were and quantified by a commercial brain wave machine. EEG was collected at frontal (e.g., Fz) and parietal (e.g., Pz) electrodes while subjects relaxed. EEG was analyzed using computer programs that measured slow-frequency EEG waves known as delta (1.5-4.5 cycles/second [cps]), theta-1 (4.5-6.0 cps), theta-2 (6.0-7.7 cps), and alpha-1 (7.8-10.0 cps), and higher frequency waves. Generally, delta, alpha-1 and theta waves reflect deactivation of the brain activity, while higher frequency waves reflect greater brain activation. Brain activity was quantified as the natural log of EEG power [microvolts squared] as determined by the fast Fourier mathematical algorithm. Days post quit were components of Time. The primary focus was on changes in the individual subject's log theta-1, theta-2, and alpha-1 power at post-quit points in time minus the log values at the pre-quite baseline.</description>
          <population>For the currently reported analyses, only individuals complying with the study requirements, including biochemically verified smoking abstinence, were assessed. Future analyses will include individuals who complied to certain critical endpoints.</population>
          <units>Change in log EEG [microvolts squared]</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day-3 Change in log Theta-1 EEG Power Fz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".055" spread=".061"/>
                    <measurement group_id="O2" value=".224" spread=".066"/>
                    <measurement group_id="O3" value=".234" spread=".066"/>
                    <measurement group_id="O4" value="-.094" spread=".071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-24 Change in log Theta-1 EEG Power Fz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".194" spread=".068"/>
                    <measurement group_id="O2" value=".198" spread=".074"/>
                    <measurement group_id="O3" value=".258" spread=".074"/>
                    <measurement group_id="O4" value="-.060" spread=".080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-45 Change in log Theta-1 Power Fz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".232" spread=".055"/>
                    <measurement group_id="O2" value=".249" spread=".060"/>
                    <measurement group_id="O3" value=".161" spread=".060"/>
                    <measurement group_id="O4" value="-.032" spread=".065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-66 Change in log Theta-1 EEG Power Fz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".431" spread=".075"/>
                    <measurement group_id="O2" value=".407" spread=".081"/>
                    <measurement group_id="O3" value=".184" spread=".081"/>
                    <measurement group_id="O4" value="-.026" spread=".087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-3 Change in log Theta-2 Power Fz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".062" spread=".077"/>
                    <measurement group_id="O2" value=".088" spread=".083"/>
                    <measurement group_id="O3" value=".249" spread=".083"/>
                    <measurement group_id="O4" value="-.070" spread=".090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-24 Change in log Theta-2 Power Fz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".251" spread=".087"/>
                    <measurement group_id="O2" value=".150" spread=".094"/>
                    <measurement group_id="O3" value=".278" spread=".094"/>
                    <measurement group_id="O4" value="-.042" spread=".101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-45 Change in log Theta-2 Power Fz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".319" spread=".074"/>
                    <measurement group_id="O2" value=".248" spread=".081"/>
                    <measurement group_id="O3" value=".278" spread=".094"/>
                    <measurement group_id="O4" value=".054" spread=".087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-66 Change in log Theta-2 Power Fz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".504" spread=".092"/>
                    <measurement group_id="O2" value=".502" spread=".100"/>
                    <measurement group_id="O3" value=".205" spread=".100"/>
                    <measurement group_id="O4" value=".001" spread=".107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-3 Change in log Alpha-1 Power Pz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.023" spread=".103"/>
                    <measurement group_id="O2" value=".155" spread=".112"/>
                    <measurement group_id="O3" value=".184" spread=".112"/>
                    <measurement group_id="O4" value="-.004" spread=".121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-24 Change in log Alpha-1 Power Pz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".139" spread=".099"/>
                    <measurement group_id="O2" value=".301" spread=".107"/>
                    <measurement group_id="O3" value=".276" spread=".107"/>
                    <measurement group_id="O4" value="-.001" spread=".115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 45 Change in log Alpha-1 Power Pz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".292" spread=".099"/>
                    <measurement group_id="O2" value=".261" spread=".107"/>
                    <measurement group_id="O3" value=".259" spread=".107"/>
                    <measurement group_id="O4" value=".021" spread=".115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 66 Change in log Alpha-1 Power Pz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".339" spread=".099"/>
                    <measurement group_id="O2" value=".459" spread=".107"/>
                    <measurement group_id="O3" value=".292" spread=".107"/>
                    <measurement group_id="O4" value=".017" spread=".116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed-model repeated measures multivariate analyses of variance assessed Treatment x Day of abstinence (days 3, 24, 45, and 66) based on changes from pre-quit baseline to values of the four post-quit time points (days 3, 24, 45, and 66).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>P values are adjusted for multiple comparisons except for specific a priori directional predictions.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Log of Smoking Withdrawal Scores (Mood, and Depressive Symptoms) From Baseline Across 66 Days of Abstinence</title>
        <description>Changes in log from baseline in the widely used Shiffman-Jarvik Withdrawal &quot;craving&quot; and &quot;psychological symptom&quot; scores through 66 days of abstinence. Post-quit changes were assessed at days 3, 24, 45, and 66 of abstinence. The maximal range of value raw for craving is from &quot;5&quot; = (no craving) to &quot;47&quot; (maximally strong craving), while that for psychological symptoms is from &quot;5&quot; (no symptoms) to &quot;60&quot; (maximally intense symptoms of across multiple symptoms). Because the subtraction of logs is equivalent to the ratio of the two scores, a difference in logs (base 10) with a value of &quot;1&quot; is equal to an increase by a factor of 10, while a value of &quot;0&quot; is no change, and values of less than &quot;0&quot; are decreases below baseline values.</description>
        <time_frame>Changes in log withdrawal symptoms from baseline through 66 days of abstinence</time_frame>
        <population>Analysis population included only those individuals who complied fully with study requirements through 67 days of abstinence.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Patch</title>
            <description>21mg, 14mg, 7mg
Nicotine: Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days</description>
          </group>
          <group group_id="O2">
            <title>Bupropion SR</title>
            <description>150 mg bid bupropion SR
Bupropion SR: 150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Patch and Placebo Pill</title>
            <description>Placebo patch same size as active patches
Placebo pill and Placebo Patch: 150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days.</description>
          </group>
          <group group_id="O4">
            <title>Delayed-quit Control</title>
            <description>Smoke for 67 days while others have quit, then quit.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Log of Smoking Withdrawal Scores (Mood, and Depressive Symptoms) From Baseline Across 66 Days of Abstinence</title>
          <description>Changes in log from baseline in the widely used Shiffman-Jarvik Withdrawal &quot;craving&quot; and &quot;psychological symptom&quot; scores through 66 days of abstinence. Post-quit changes were assessed at days 3, 24, 45, and 66 of abstinence. The maximal range of value raw for craving is from &quot;5&quot; = (no craving) to &quot;47&quot; (maximally strong craving), while that for psychological symptoms is from &quot;5&quot; (no symptoms) to &quot;60&quot; (maximally intense symptoms of across multiple symptoms). Because the subtraction of logs is equivalent to the ratio of the two scores, a difference in logs (base 10) with a value of &quot;1&quot; is equal to an increase by a factor of 10, while a value of &quot;0&quot; is no change, and values of less than &quot;0&quot; are decreases below baseline values.</description>
          <population>Analysis population included only those individuals who complied fully with study requirements through 67 days of abstinence.</population>
          <units>log (base 10) units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day-3 Change in log Shiffman Craving</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.006" spread=".038"/>
                    <measurement group_id="O2" value=".045" spread=".042"/>
                    <measurement group_id="O3" value=".094" spread=".040"/>
                    <measurement group_id="O4" value="-.045" spread=".046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-24 Change in log Shiffman Craving</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.187" spread=".054"/>
                    <measurement group_id="O2" value="-.199" spread=".060"/>
                    <measurement group_id="O3" value="-.045" spread=".057"/>
                    <measurement group_id="O4" value="-.059" spread=".066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-45 Change in log Shiffman Craving</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.273" spread=".047"/>
                    <measurement group_id="O2" value="-.201" spread=".052"/>
                    <measurement group_id="O3" value="-.132" spread=".050"/>
                    <measurement group_id="O4" value="-.043" spread=".057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-66 Change in log Shiffman Craving</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.236" spread=".054"/>
                    <measurement group_id="O2" value="-.230" spread=".059"/>
                    <measurement group_id="O3" value="-.205" spread=".057"/>
                    <measurement group_id="O4" value="-.075" spread=".065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-3 Change in log Shiffman Psych Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".089" spread=".032"/>
                    <measurement group_id="O2" value=".210" spread=".035"/>
                    <measurement group_id="O3" value=".172" spread=".034"/>
                    <measurement group_id="O4" value=".016" spread=".039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-24 Change in log Shiffman Psych W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".065" spread=".031"/>
                    <measurement group_id="O2" value=".102" spread=".034"/>
                    <measurement group_id="O3" value=".076" spread=".033"/>
                    <measurement group_id="O4" value="-.025" spread=".038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-45 Change in log Shiffman Psych Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".008" spread=".031"/>
                    <measurement group_id="O2" value=".063" spread=".034"/>
                    <measurement group_id="O3" value=".039" spread=".033"/>
                    <measurement group_id="O4" value="-.017" spread=".038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-66 Change in log Shiffman Psych Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".068" spread=".037"/>
                    <measurement group_id="O2" value=".032" spread=".041"/>
                    <measurement group_id="O3" value=".029" spread=".039"/>
                    <measurement group_id="O4" value="-.012" spread=".045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the day of consent through one year after the 67-day post-quit treatment phase.</time_frame>
      <desc>Questionnaires at approximately weekly intervals through one year after the 67-day post-quit treatment phase. Then every 3 months until a year after the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bupropion SR</title>
          <description>150 mg bid bupropion SR
Bupropion SR: 150 encapsulated pill, 3 days 1x/day then 56 days at 2x/day, then 3 day at 1x/day ramp-down.</description>
        </group>
        <group group_id="E2">
          <title>Nicotine Patch</title>
          <description>21mg, 14mg, 7mg
Nicotine: Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days</description>
        </group>
        <group group_id="E3">
          <title>Placebo Patch and Placebo Pill</title>
          <description>Placebo patch same size as active patches
Placebo pill and Placebo Patch: 150 encapsulated placebo pill,3 days 1x/day then 56 days at 2x/day, then 3 days at 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days.</description>
        </group>
        <group group_id="E4">
          <title>Delayed-quit Control</title>
          <description>Smoke for 67 days while others have quit, then quit.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <description>Self-reported &quot;dry mouth&quot; on standard questionnaire</description>
                <counts group_id="E1" events="53" subjects_affected="13" subjects_at_risk="32"/>
                <counts group_id="E2" events="34" subjects_affected="13" subjects_at_risk="38"/>
                <counts group_id="E3" events="27" subjects_affected="9" subjects_at_risk="35"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <description>Self-reported &quot;headaches&quot;</description>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dizzyness</sub_title>
                <description>Self-reported &quot;dizziness&quot;</description>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disturbance</sub_title>
                <description>Self-reported &quot;sleep disturbance&quot; on standard questionnaire.</description>
                <counts group_id="E1" events="42" subjects_affected="13" subjects_at_risk="32"/>
                <counts group_id="E2" events="63" subjects_affected="15" subjects_at_risk="38"/>
                <counts group_id="E3" events="54" subjects_affected="17" subjects_at_risk="35"/>
                <counts group_id="E4" events="6" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The modest sample size limited the ability to detect more subtle treatment effects. The exclusionary criteria limits generalization to excluded groups.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David G. Gilbert, Ph.D.</name_or_title>
      <organization>Southern Illinois University Carbondale</organization>
      <phone>618-45303558</phone>
      <email>dgilbert@siu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

